Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) EPS (Weighted Average and Diluted) (2019 - 2025)

Standard Biotools (LAB) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.13 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 85.71% to -$0.13 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.44, a 24.14% increase, with the full-year FY2024 number at -$0.52, up 44.68% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.13 for Q3 2025 at Standard Biotools, down from -$0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.01 in Q2 2024 to a low of -$0.99 in Q1 2022.
  • A 5-year average of -$0.26 and a median of -$0.22 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 104.55% in 2024, then tumbled 600.0% in 2025.
  • Standard Biotools' EPS (Weighted Average and Diluted) stood at -$0.12 in 2021, then crashed by 116.67% to -$0.26 in 2022, then increased by 3.85% to -$0.25 in 2023, then grew by 24.0% to -$0.19 in 2024, then soared by 31.58% to -$0.13 in 2025.
  • Per Business Quant, the three most recent readings for LAB's EPS (Weighted Average and Diluted) are -$0.13 (Q3 2025), -$0.05 (Q2 2025), and -$0.07 (Q1 2025).